Marco Finati

Henry Ford Hospital

Papers

8

Total Citations

58

H-Index

5

About

Dr. Marco Finati is a leading urologic oncologist whose research focuses on optimizing surgical and oncological outcomes for upper tract urothelial carcinoma (UTUC). As a key contributor to the ROBUUST 2.0 collaborative group, Dr. Finati has spearheaded landmark studies analyzing robot-assisted nephroureterectomy (RANU) in over 1,100 patients, demonstrating its safety and mid-term oncological efficacy. His work has critically evaluated the impact of bladder cuff excision, the role of neoadjuvant chemotherapy in locally advanced disease, and the prognostic significance of diagnostic ureteroscopy—addressing contentious areas in UTUC management. Dr. Finati has also developed a pretreatment nomogram to predict muscle invasion, aiding clinical decision-making. His comparative analysis of single-dose intravesical gemcitabine versus mitomycin C after RNU provides valuable insights into postoperative chemoprophylaxis. With several highly cited publications from 2024–2025, including papers with 17 and 10 citations, Dr. Finati’s contributions are shaping evidence-based practice in robotic UTUC surgery, improving patient selection, and advancing personalized treatment strategies.

Research Focus

Key Achievements

5
H-Index
8
Papers
58
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)
17 citations · 2024
📈 Most Prolific Year: 2024 (5 Papers)
🤝 Key Collaborators: 78
🏛 Institutions: Henry Ford Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago